Intermittent fasting and GLP-1 medications continue to gain attention as effective tools for weight loss and metabolic health. Medications such as semaglutide and tirzepatide help regulate appetite, while intermittent fasting creates structured eating windows that may support calorie control and healthier habits. Together, these approaches may improve weight management for some adults struggling with obesity and related health concerns. According to National Health and Nutrition Examination Survey data, more than 42 percent of U.S. adults have obesity, highlighting the growing need for sustainable treatment strategies. 

Intermittent fasting focuses on when a person eats rather than what foods are consumed. Eating is limited to designated hours during the day, followed by periods of fasting. Research suggests this approach may improve insulin sensitivity, metabolic flexibility and inflammation levels in some individuals. GLP-1 medications complement fasting by reducing hunger signals and slowing gastric emptying, helping people feel fuller longer and reducing cravings between meals. A recent study published through the National Institutes of Health also supports the growing role of GLP-1 therapies in weight management and metabolic health. 

Medical professionals emphasize that GLP-1 medications and intermittent fasting are not appropriate for everyone and should be approached carefully. Adequate hydration, balanced nutrition and proper vitamin and mineral intake remain essential throughout treatment. Ongoing medical supervision may also help reduce side effects and improve long-term success.

At Wycoff Wellness Center, in East Lansing, patients receive individualized guidance on intermittent fasting and GLP-1 therapies designed to support long-term weight-loss success. The practice emphasizes thoughtful medical supervision, healthy lifestyle habits and personalized treatment plans to help patients safely achieve their wellness goals.